Showing results (31-40 of 39) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Oxidative Medicine and Cellular Longevity|December 30, 2021
GPX4-Regulated Ferroptosis Mediates S100-Induced Experimental Autoimmune Hepatitis Associated with the Nrf2/HO-1 Signaling PathwayLujian Zhu, Dazhi Chen, Yin Zhu, et al.Biochimica Et Biophysica Acta. Molecular Basis of Disease|September 27, 2022
A non-mitogenic FGF4 analog alleviates non-alcoholic steatohepatitis through an AMPK-dependent pathwayLuyao Wang, Wenliya Dong, Huan Gao, et al.Journal of Cellular and Molecular Medicine|December 7, 2019
microRNA-143-3p attenuated development of hepatic fibrosis in autoimmune hepatitis through regulation of TAK1 phosphorylationHanxiao Tu, Dazhi Chen, Chao Cai, et al.Infectious Microbes & Diseases|April 17, 2024
Characteristics of Liver Functions in Patients With COVID-19 and Construction of a Prognostic Evaluation Decision Model Based on Liver FunctionsTongtong Pan, Dazhi Chen, Chenwei Pan, et al.Toxicology and Applied Pharmacology|February 17, 2022
Lactobacillus rhamnosus GG combined with inosine ameliorates alcohol-induced liver injury through regulation of intestinal barrier and Treg/Th1 cellsYin Zhu, Xiaozhi Wang, Lujian Zhu, et al.Acta Pharmaceutica Sinica. B|April 4, 2024
FGF4 protects the liver from immune-mediated injury by activating CaMKKβ-PINK1 signal pathway to inhibit hepatocellular apoptosisZhifeng Huang, Tongtong Pan, Liang Xu, et al.Acta Pharmaceutica Sinica. B|June 3, 2024
Erratum: Author correction to 'FGF4 protects the liver from immune-mediated injury by activating CaMKKβ-PINK1 signal pathway to inhibit hepatocellular apoptosis' [Acta Pharm Sin B 14 (2024) 1605-1623]Zhifeng Huang, Tongtong Pan, Liang Xu, et al.Hepatology (Baltimore, Md.)|February 26, 2025
Repression of the ERRγ-CYP2E1 pathway by FGF4 mitigates alcohol-associated liver injuryLuyao Wang, Wenliya Dong, Lei Fan, et al.Hepatology (Baltimore, Md.)|February 13, 2022
FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axisLintao Song, Luyao Wang, Yushu Hou, et al.Pageof 4